| Old Articles: <Older 4001-4010 Newer> |
|---|
 |
The Motley Fool
August 9, 2007
Brian Orelli |
Acquisition Raises Barr Half a year after acquiring a giant competitor, Barr Pharmaceuticals results appear to be on track to increase year-over-year revenues.   |
The Motley Fool
August 8, 2007
Brian Lawler |
Dendreon Plods Along The turbulent drug developer releases its second-quarter financial results. Investors, take note. |
The Motley Fool
August 8, 2007
Ryan Fuhrmann |
Hospira Looks to Deliver Will a recent acquisition boost drug delivery firm Hospira's growth prospects? The new Mayne Pharma Limited division played a primary role in delivering an impressive 30% reported sales growth. |
The Motley Fool
August 8, 2007
Brian Orelli |
Onyx Is Almost There Onyx Pharmaceutical narrowed losses for the quarter, and things should improve even more in the months to come, even as their bottom line is still being hampered by endless clinical trials. |
The Motley Fool
August 8, 2007
Brian Lawler |
Array's Bright Pipeline Array BioPharma announces its goals for the months ahead in its fourth-quarter results. What is interesting is the varied mix of new compounds in their pipeline. |
The Motley Fool
August 8, 2007
Brian Orelli |
Inverness Does It Again Another month, another company to buy. Is Inverness Medical Innovations finally spreading itself too thin? The company just announced its seventh acquisition or joint venture in 18 months. |
The Motley Fool
August 8, 2007
Brian Orelli |
Is Indevus Headed to the Black? Two new drugs should help turn things around at specialty pharmaceutical company Indevus. The company is not in the black yet, but they have been on a roll these last three months with FDA approvals of two new drugs. |
The Motley Fool
August 8, 2007
Rich Smith |
Foolish Forecast: Watch for ViaCell to Tip Its Hand Will second-quarter results from cord-blood storage specialist ViaCell meet or exceed the relatively low management expectations? And will the next quarter improve, as the company has previously predicted? |
The Motley Fool
August 7, 2007
Brian Lawler |
Nektar Makes a Deal Nektar Therapeutics signs a deal with Bayer AG in an effort to move itself closer to profitability. In return, Bayer gets a co-promotion profit-sharing deal in the U.S., and commercialization rights elsewhere. |
The Motley Fool
August 7, 2007
Brian Lawler |
Encysive's Congested Sales Failure Encysive Pharmaceuticals releases quarterly results that reveal a company with problems. Its cost structure is way out of line for a drugmaker of its size and potential. |
| <Older 4001-4010 Newer> Return to current articles. |
